What Halozyme Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 39 | 106 |
| Total trades | 50 | 185 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 180,000 | 787,951 |
| Disposed | 205,852 | 727,166 |
| Net activity | −25,852 | +60,785 |
Common stock only — 3 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO | Oct 08 | Open-market sale · S | −200 | $110.51 | −$22.1K | 767,780 |
| Torley Helen | PRESIDENT AND CEO | Oct 08 | Open-market sale · S | −11,900 | $110.00 | −$1.31M | 767,980 |
| Torley Helen | PRESIDENT AND CEO | Oct 08 | Open-market sale · S | −3,090 | $108.91 | −$337K | 779,880 |
| Torley Helen | PRESIDENT AND CEO | Oct 08 | Open-market sale · S | −4,810 | $108.18 | −$520K | 782,970 |
| Torley Helen | PRESIDENT AND CEO | Oct 08 | Exercise / conversion · M | +20,000 | $18.41 | +$368K | 787,780 |
| Torley Helen | PRESIDENT AND CEO | Oct 07 | Open-market sale · S | −200 | $113.69 | −$22.7K | 767,780 |
| Torley Helen | PRESIDENT AND CEO | Oct 07 | Open-market sale · S | −900 | $112.78 | −$102K | 767,980 |
| Torley Helen | PRESIDENT AND CEO | Oct 07 | Open-market sale · S | −10,300 | $111.84 | −$1.15M | 768,880 |
| Torley Helen | PRESIDENT AND CEO | Oct 07 | Open-market sale · S | −8,600 | $111.03 | −$955K | 779,180 |
| Torley Helen | PRESIDENT AND CEO | Oct 07 | Exercise / conversion · M | +20,000 | $18.41 | +$368K | 787,780 |
| Torley Helen | PRESIDENT AND CEO | Oct 06 | Open-market sale · S | −1,780 | $110.81 | −$197K | 767,780 |
| Torley Helen | PRESIDENT AND CEO | Oct 06 | Open-market sale · S | −9,920 | $109.89 | −$1.09M | 769,560 |
| Torley Helen | PRESIDENT AND CEO | Oct 06 | Open-market sale · S | −6,000 | $109.33 | −$656K | 779,480 |
| Torley Helen | PRESIDENT AND CEO | Oct 06 | Open-market sale · S | −2,300 | $107.90 | −$248K | 785,480 |
| Torley Helen | PRESIDENT AND CEO | Oct 06 | Exercise / conversion · M | +20,000 | $18.41 | +$368K | 787,780 |
| Posard Matthew L. | Director | Oct 01 | Open-market sale · S | −100 | $110.04 | −$11K | 53,609 |
| Posard Matthew L. | Director | Oct 01 | Open-market sale · S | −1,100 | $109.57 | −$121K | 53,709 |
| Posard Matthew L. | Director | Oct 01 | Open-market sale · S | −3,300 | $108.45 | −$358K | 54,809 |
| Posard Matthew L. | Director | Oct 01 | Open-market sale · S | −730 | $107.17 | −$78.2K | 58,109 |
| Daly James M | Director | Oct 01 | Grant / award · A | +1,169 | — | — | 1,169 |
Loading...
